Revenue

A new partnership uses AI to analyze imaging, clinical, and molecular data, offering unprecedented accuracy in predicting breast cancer recurrence years later.

After major setbacks, a surge of innovative drugs is set to transform the ALS market. We decode the science, the money, and what it means for patients.

NREF's massive capital raise signals strong investor confidence. We dive into what this bold move reveals about the market and income-seeking investors.

An energy services giant just sold its nuclear arm to a startup in a stock deal. It's a strategic pivot to mass-produce reactors for the AI power crunch.

Serve Robotics and Uber Eats launch sidewalk robots in Alexandria, Va., testing the scalability, economics, and public acceptance of last-mile automation.

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.

Match Group bets big on the future of dating, spinning out an AI venture while a new CEO steers Hinge toward its projected $1 billion revenue goal.

Darling Ingredients' new venture with Tessenderlo isn't just a merger; it's a strategic move to dominate the booming collagen and nutrition market.

With Nick Saban as an investor, an iconic Alabama resort gets new owners. It's a high-stakes play balancing legacy, luxury, and local economic impact.

A $3 billion drop in assets at AllianceBernstein, driven by client withdrawals in a flat market, signals a deeper challenge for active asset managers.

Ryman Hospitality's upcoming earnings call is a bellwether for conventions and country music. Here’s what investors are watching in its dual-engine strategy.

Beyond the headlines of a $592M debt reduction, McGraw Hill is executing a dual strategy: fortifying its finances to fund a digital and AI-driven future.

Nordson's record earnings reveal the high-tech backbone of premium goods and a resilient, behind-the-scenes investment in the high life.

As CEO De Lyle Bloomquist announces his retirement, Rayonier Advanced Materials seeks a new leader to steer its ambitious 'BioFuture' strategy amid market volatility.

The lab outfitter's Nu Aire acquisition fuels record revenue, but integration costs and market volatility paint a complex picture of strategic investment.

T1 Energy is raising massive capital for its G2_Austin plant and to comply with federal rules, betting big on an American-made clean energy supply chain.

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

Fintech firm Nayax's oversubscribed Israeli offering signals strong investor confidence and fuels its ambitious plan for global expansion through acquisitions.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.